Global Blood Therapeutics Inc. (NASDAQ:GBT) has been given a $47.00 target price by research analysts at Roth Capital in a research report issued on Monday. The firm currently has a “buy” rating on the stock. Roth Capital’s target price would suggest a potential upside of 152.01% from the company’s previous close.

GBT has been the topic of several other research reports. Morgan Stanley restated a “buy” rating and set a $62.00 price objective on shares of Global Blood Therapeutics in a research note on Sunday, August 14th. Zacks Investment Research cut Global Blood Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, November 14th. Wells Fargo & Co. initiated coverage on Global Blood Therapeutics in a research note on Friday, September 30th. They set an “outperform” rating and a $23.05 price objective on the stock. Cowen and Company restated an “outperform” rating and set a $83.00 price objective (up previously from $80.00) on shares of Global Blood Therapeutics in a research note on Wednesday, October 26th. Finally, Wedbush restated an “outperform” rating and set a $66.00 price objective on shares of Global Blood Therapeutics in a research note on Monday, August 22nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $47.86.

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics (NASDAQ:GBT) opened at 18.65 on Monday. The firm’s 50-day moving average price is $18.02 and its 200 day moving average price is $19.20. The firm’s market cap is $695.94 million. Global Blood Therapeutics has a 52-week low of $12.24 and a 52-week high of $51.95.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.58) EPS for the quarter, meeting analysts’ consensus estimates of ($0.58). During the same period in the previous year, the company posted ($0.90) earnings per share. On average, equities research analysts forecast that Global Blood Therapeutics will post ($2.40) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Global Blood Therapeutics Inc. (GBT) Given a $47.00 Price Target by Roth Capital Analysts” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/global-blood-therapeutics-inc-gbt-given-a-47-00-price-target-by-roth-capital-analysts.html.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Global Blood Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 49,739 shares of the company’s stock worth $1,147,000 after buying an additional 775 shares during the last quarter. Rhumbline Advisers raised its position in shares of Global Blood Therapeutics by 10.4% in the third quarter. Rhumbline Advisers now owns 12,886 shares of the company’s stock worth $297,000 after buying an additional 1,215 shares during the period. Teachers Advisors LLC raised its position in shares of Global Blood Therapeutics by 11.7% in the third quarter. Teachers Advisors LLC now owns 24,870 shares of the company’s stock worth $573,000 after buying an additional 2,598 shares during the period. American International Group Inc. raised its position in shares of Global Blood Therapeutics by 104.2% in the second quarter. American International Group Inc. now owns 8,096 shares of the company’s stock worth $134,000 after buying an additional 4,131 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Global Blood Therapeutics by 101.7% in the second quarter. Nationwide Fund Advisors now owns 9,100 shares of the company’s stock worth $151,000 after buying an additional 4,588 shares during the period. Institutional investors and hedge funds own 56.01% of the company’s stock.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders.

5 Day Chart for NASDAQ:GBT

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.